Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07115004 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

A Phase 3 study of Von Willebrand Disease (VWD), sponsored by Vega Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
60
Enrollment target
4
Study locations

NCT07115004 is a Phase 3 study of Von Willebrand Disease (VWD) that is actively recruiting participants, run by Vega Therapeutics. The registered enrollment target is 60 participants, below the 94-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (36% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07115004, a Phase 3 study of Von Willebrand Disease (VWD), is actively recruiting participants, sponsored by Vega Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
60 participants
Enrollment target
4
Study locations

Study Summary

This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)

Conditions Studied

Von Willebrand Disease (VWD)

Interventions

  • DRUG VGA039

Study Locations (4)

Arkansas

  • Arkansas Children's Hospital - Little Rock

North Carolina

  • Science 37, Inc. (Virtual Clinical MetaSite) - Morrisville

Pennsylvania

  • Hemophilia Center of Western PA - Pittsburgh

Washington

  • Washington Center for Bleeding Disorders - Seattle

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-10-15
Est. Completion 2028-10
Phase Phase 3

Sponsor

Vega Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07115004

The ClinicalTrials.gov registry entry for NCT07115004 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (36% lower). The listed sponsor is Vega Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Von Willebrand Disease (VWD) appearing as the primary indexed condition, and to 1 intervention - of which VGA039 is the first listed.

NCT07115004 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arkansas, North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07115004 about?

NCT07115004 is a clinical study titled "Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)". This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)

What is the current status of trial NCT07115004?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-10-15. Estimated completion is 2028-10.

What conditions does trial NCT07115004 study?

This clinical trial studies the following conditions: Von Willebrand Disease (VWD).

What interventions are being tested in trial NCT07115004?

The interventions under investigation include: VGA039 (DRUG).

Who is sponsoring clinical trial NCT07115004?

This trial is sponsored by Vega Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07115004 being conducted?

This trial has 4 study locations across Arkansas, North Carolina, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Von Willebrand Disease (VWD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Von Willebrand Disease (VWD)

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.